WO1995007091A1

WO1995007091A1 - Uses of vegetable oils

Info

Publication number: WO1995007091A1
Application number: PCT/EP1994/003020
Authority: WO
Inventors: Kerstin Bohnsack; Riku Rautsola; Ernst Weiland
Original assignee: Beiersdorf Ag
Priority date: 1993-09-10
Filing date: 1994-09-09
Publication date: 1995-03-16
Also published as: DE4330664A1; AU7657094A; JPH09502196A; EP0720481A1

Abstract

The invention pertains to the use of: I. a) one ore more components selected from the group of vegetable oils and vegetable fats, oleic acid or its derivatives, linoleic acid or its derivatives, and mixed di- or triglycerides or mixed phospholipids with two or more acids from the group made up of oleic acid, linoleic acid and fatty acids of the n-3 series or n-6 series, where preferably at least one of the acids is oleic acid or linoleic acid, and b) as needed, at least one animal fat or animal oil, and c) as needed, at least one fatty acid of the n-3 series or n-6 series or their respective derivatives; and II. individual active agents and combinations as per I., as needed in combination with one or more components selected from one or more of the following groups of d) trace elements, e) minerals, f) minerals, f) vitamins, g) amino acids, h) anti-inflammatory and/or immunosuppressive agents, i) antipsoriatics, j) keratolytics and/or k) urea, for treatment and prophylaxis of inflammatory or immunological diseases, diabetes, alcoholism and wounds.

Description

description

Uses of vegetable oils

The invention relates to new uses of vegetable oils and their components.

Saturated and unsaturated fatty acids are contained in the cell membrane of cells. The concentration of unsaturated fatty acids plays a role in the barrier properties of the skin as well as in the reactivity of cells in inflammatory and immunological processes such as z. B. in psoriasis or atopic dermatitis.

The current state of therapy for skin diseases, such as psoriasis therapy, has disadvantages. Systemic therapy is only possible with strong side effects, e.g. B. in the treatment with cyclosporin (kidney-toxic, immunosuppressive), retinoids (teratogenic, blood pressure and serum lipid value increasing), methotrexate (hepatotoxic), UV therapy (PUVA, UV-B, carcinogen). Therefore long-term therapy is not possible. After stopping, the symptoms return immediately. Interval therapy (between the episodes of the disease) and prophylaxis are also not possible because of the side effects. The same applies to other inflammatory dermatoses, such as. B. Atopic dermatitis (glucocorticoid therapy).

Topical therapy is only possible in the case of small-scale infestation in areas of the body that are accessible to the patient. Complicated to use is e.g. B. the dithranol therapy. It cannot be used on hard-to-reach areas such as the back, mucous membranes or hairy head.

Furthermore, mainly external therapeutic agents for eczema treatment containing coconut oil and palm kernel oil are known, which are characterized by a high content of lauric acid and myristic acid. They have not always proven to be beneficial.

SPARE BLADE (RULE 26) The object of the invention is, in particular, to enable effective prophylaxis, interval and long-term therapy without any particular side effects, which is also suitable without problems for particularly needy patients, such as children or the elderly. It should also be easy to use.

The invention relates to the use of

I. a) one or more components selected from the group of vegetable oils and vegetable fats and oleic acid or its derivatives and linoleic acid or its derivatives and the mixed di- or tri-glycerides or mixed phospholipids with two or more acids from the group, formed from oleic acid, linoleic acid and fatty acids of the n-3 series or n-6 series, preferably at least one of the acids being oleic acid or linoleic acid, and

(b) where appropriate, at least one animal fat or animal oil; and

c) optionally at least one fatty acid of the n-3 series or n-6 series or in each case their derivatives,

and

II. Of individual active substances and combinations according to I., each optionally in combination with one component or more components each selected from one or more of the following groups of

d) trace elements, e) minerals, f) vitamins, g) amino acids, h) anti-inflammatory and / or immunosuppressive substances i) antipsoriatics, j) keratolytics and / or k) urea, for the treatment and prophylaxis of inflammatory or immunological diseases, diabetes, alcoholism and wounds.

One or more components from each of only one of groups d) to k) are preferably used.

If several of the active ingredients a) -k) are used, they form a mixture.

Vegetable oils or vegetable fats with fatty acids which have at least one double bond, but in particular have one or two double bonds, are particularly suitable. These fatty acids with 16-20 carbon atoms, but in particular 18 carbon atoms, are preferred.

Vegetable oils and fats with a high content of oleic acid and / or linoleic acid are preferably used. This applies to the case that they are used according to I. a) alone or in a mixture with components a), but also for combinations with the other active ingredients.

Suitable oils are e.g. B. castor oil, sunflower oil, rapeseed oil, sesame oil, linseed oil, safflower oil, cottonseed oil, palm oil, palm kernel oil, olive oil, babassufett, corn oil, wheat germ oil, pumpkin seed oil, rice germ oil, rape oil, coconut oil, tall oil, cocoa butter, shea butter, borne tallow.

Sunflower oil, soybean oil, peanut oil, rapeseed oil, sesame oil, safflower oil, tall oil, linseed oil, rapeseed oil, mustard oil, olive oil, tea seed oil, coriander oil, safflower oil, safflower oil, borage oil, evening primrose oil, fennel oil, and blackberry seed oil.

Olive oil, corn oil, peanut oil, soybean oil, sunflower oil and wheat germ oil are particularly preferred.

Olive oil, sunflower oil, corn oil, wheat germ oil or tea seed oil are particularly preferred.

All of the above-mentioned oils and fats can be used alone or as mixtures and are particularly suitable for the prophylaxis and treatment of psoriasis or atopy.

^" SPARE BLADE (RULE 26) Olive oil has also been used as a comparative substance in the analysis of fish oils for the treatment of psoriasis. However, it only served as an ineffective placebo, because it is not considered by the specialist as an active ingredient for the treatment of psoriasis or other diseases.

Surprisingly, it has now been found that olive oil can be used as an active ingredient just like the other active ingredients according to the invention for the treatment of the diseases or conditions mentioned according to the invention, in particular psoriasis.

Olive oil, oleic acid and / or linoleic acid or their derivatives are particularly preferably used, in particular also when two or more components a) are used or when combinations with other active compounds according to the invention are used.

Animal fats or animal oils which may be used are tallow or lard, for example beef tallow, milk fat, mutton tallow, hoof oil, pork lard, goose lard, marine oils such as whale oil, sperm oil, seal oils, herring oils such as e.g. B. mackerel oil, pilchard oil, menhaden oil. Fish oils are preferred.

Particularly preferred are optionally used fatty acids of the n-3 series or their derivatives z. B. alpha-linolenic acid or its metabolites or their derivatives, especially the acids 18: 4n-3, 20: 4n-3, 20: 5n-3, 22: 5n-3, 22: 6n-3. Eicosapentaenoic acid (EPA), docosatetraenoic acid, docosapentaenoic acid and docosahexaenoic acid and their derivatives are particularly preferred. EPA and its derivatives are particularly preferred.

Preferred n-6 fatty acids are gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) and arachidonic acid (AA).

The acids of the invention can be administered in the form of the acid itself or as a derivative, e.g. B. ester, amide, salt or any other functional derivative which is capable of being converted into a biologically active form of the acid in the body and which can come from natural or synthetic sources.

SPARE BLADE (RULE 26) Suitable physiologically functional derivatives according to the invention, which are converted to acids in the body and follow the known metabolic pathway, are, for. B. physiologically acceptable salts, esters, especially glycerides and alkyl esters (z. B. C- _| - to C4-alkyl esters, preferably ethyl esters), amides (z. B. Cη-C ^ mono- or dialkylamides) and phospholipids. Indirect identification of useful derivatives occurs because they have about the same effect in the body as the acid itself.

Mixed glycerides or phosphorus lipids are known or can be obtained by known esterification processes or transesterification processes.

Preferred combinations are:

Olive oil combined with fatty acids of the n-3 and / or n-6 series, in particular EPA and / or GLA or their derivatives in each case,

Oleic acid, combined with fatty acids of the n-3 and / or n-6 series, in particular EPA and / or GLA or their derivatives,

- Linoleic acid, combined with fatty acids of the n-3 and / or n-6 series, in particular EPA and / or GLA or their derivatives.

Corn oil, peanut oil, soybean oil, sunflower oil, wheat germ oil or tea seed oil can also be used advantageously instead of olive oil. The weight percentages given below are also preferred for these combinations.

The combinations of the fatty acids of the n-3 and n-6 series are also advantageously used in the form of natural fats and oils in which they are present, for example fish oils, borage oil, evening primrose oil or currant seed oil.

Combinations of olive oil and / or oleic acid and / or linoleic acid are also preferably used, in particular also in the above combinations.

Preferred trace elements that may be used in combination are:

Iron,

Fluorine,

Iodine,

Copper,

Zinc,

Manganese,

Silicon,

SPARE BLADE (RULE 26) Molybdenum,

Selenium,

Vanadium,

Chrome,

Cobalt,

Nickel and / or

Aluminum.

Iron is preferred. It can be used in a known manner as a salt or iron complex, preferably in amounts which allow the known daily doses of 1 to 100 mg, preferably 5-30 mg per day (calculated as iron) to be achieved.

Selenium, in the form of known selenium compounds, e.g. B: in usual daily doses of 0.05-0.1 mg (based on selenium), in deficiency conditions also up to 0.6 mg.

Preferred minerals, sodium, potassium and / or calcium compounds used in combination, in particular in the form of their phosphates or chlorides. Calcium chloride is particularly preferred.

Preferred vitamins that are optionally used in combination are:

Retinol (vitamin A)

Calciferol (Vitamin D) α-tocopherol (Vitamin E)

Phytomenadione (Vitamin K- _j )

Thiamine (vitamin B ^)

Riboflavin (Vitamin B ₂ )

Pyridoxine (pyridoxal, vitamin B ₆ )

Nicotinamide (niacin)

Pantothenic acid

Biotin

Folic acid

Cyanocobalamin (vitamin B ₂ )

Ascorbic acid (vitamin C).

SPARE BLADE (RULE 26) Vitamin A, vitamin A acid, retinol, retinol acetate, vitamin E, tocopherol acetate, vitamin D, e.g. B. D--, D ₂ , D ₃ , and / or vitamin C.

Preferred amino acids which are optionally used in combination are those amino acids which are contained in collagen, elastin, glycosaminoglycans or hyaluronic acid, in particular arginine, proline, hydroxyproline, alanine, valine, cystine, glycine, lysine and hydroxylysine.

Preferred anti-inflammatory and / or immunosuppressive substances that are optionally used in combination are corticosteroids (eg: prednisolone, triamcinolone), methotrexate and cyclosporin.

Are preferred as optionally used in combination antipsoriatics, eg. B. dithranol, fumaric acid, for example as disodium salt or ethyl hydrogen fumarate and 8-methoxypsoralen.

Salicylic acid is preferred as the keratolytic agent optionally used in combination.

The antipsoriatics, keratolytics and urea are particularly preferably administered externally, especially in topical preparations. Antipsoriatics can be contained in amounts of 0.1-5% by weight, preferably 2-4% by weight, in each case based on the entire preparation. Keratolytics can be contained in amounts of 1-5% by weight, preferably 2-4% by weight, based in each case on the entire preparation. Urea can be present in amounts of 0.01-30% by weight, preferably 0.1-12% by weight, based in each case on the entire preparation.

The inflammatory and immunological diseases according to the invention are in particular inflammatory or immunologically / allergically caused diseases of the skin, the appendages of the skin, the mucous membranes, the intestine, the cartilage, the diseases associated with the atopic form, and acute and chronic wounds, alcoholism and diabetes.

The active compounds according to the invention are particularly suitable for the prophylaxis and treatment of diseases in accordance with the assignment and description of the standard work O. Braun-Falco, G. Plewig, H. H. Wolff, R. K. Winkelmann, Dermatology, Springer Verlag 1984, preferably as on pages XV-XXV

SPARE BLADE (RULE 26) specified, in particular dermatitis (e.g. contact dermatitis) and eczema (e.g.: atopic dermatitis), drug reactions, urticaria diseases, physically and chemically related skin disorders (e.g. sunburn), erythematous, erythematosquamous and papular skin disorders (e.g. Psoriasis), blistering diseases (e.g. pemphigus), sterile pustular diseases, inflammatory or immunologically related keratoses (e.g. ichthyoses, winter xerosis), inflammatory or immunological disorders of the connective tissue (e.g. scleroderma, lupus), des Cartilage, neurological or psychogenic skin diseases (e.g. pruritus), inflammatory diseases of the sebaceous follicles (e.g. acne) and mucous membranes of non-bacterial origin (e.g. balanitis, vulvovaginitis,

Mouth inflammation), porphyrias, acute and chronic wounds (e.g. pressure ulcers, ulcus cruris) as well as other diseases related to the atopic form (e.g. allergies, asthma, allergic rhinitis, Crohn's disease, ulcerative colitis, nephrotic syndrome, otitis media , benign breast disease), alcoholism, diabetes.

For prophylaxis and interval treatment, the active ingredients are administered in order to reduce the frequency and severity of manifestations of the diseases. Treatment in the manifest stage leads to its shortening and alleviation of the symptoms.

Di- and triglycerides, Cj-C2-alkyl esters or C- _| are preferred -C2 mono- or dialkylamides or water-soluble salts of the acids according to the invention, in particular the alkali metal salts, e.g. B: the sodium salt or the potassium salt and also the ammonium salt. The calcium or magnesium salt and the salts of organic bases, e.g. B: Amines such as ethanolamine, ethylene diamine and morpholine. However, the fats and oils per se are preferred.

Di- and triglycerides are particularly preferred in the treatment of disturbed keratinization and psoriasis or atopy.

The active ingredients are surprisingly suitable for curing the conditions mentioned, in particular for long-term therapy, interval therapy and prophylaxis.

The prophylaxis and treatment of psoriasis and

Atopic dermatitis.

SPARE BLADE (RULE 26) Combinations with drugs according to II. Are advantageous since their daily doses can be reduced, so that long-term therapies in particular are possible.

One of the components of a) is preferably used alone or as a mixture of two or more of the components of a).

The active substances from a) can also be used together with substances from b) and / or c). These combinations preferably contain high proportions by weight of one or more components of a), preferably a predominant proportion by weight of a). Combinations are preferred which contain a) in amounts of 50-99% by weight, in particular 60-90% by weight or also 70-85% by weight, based in each case on combinations of a), b) and c ), where b) and / or c) are present in amounts which correspond to the addition to 100%. If appropriate, components b) and / or c) are each preferably present in amounts of 1-25% by weight. Combinations of substances a) and c) are preferred, in particular also in the amounts specified above.

Optionally, active ingredients according to I. a) -c) are combined with components according to II. D) -k). The components d) -k) are preferably selected in such amounts that the daily doses for oral administration are those as described in the literature and e.g. B. are recommended as a daily requirement for humans. This simple quantity adjustment is readily possible for the person skilled in the art. Well-suited values are e.g. B. in

H.D. Belitz, W. Grosch Textbook of Food Chemistry 2nd Edition Springer Verlag, 1985 and

Red list 1994

List of medicinal products from BPI Editio Cantor Verlag

specified.

REPLACEMENT BLADE (RULE 26) The following daily doses for vitamin intake are particularly preferred:

Vitamin unit

A IE 5000-6000

D IE 400 = 10 μg

E IE 15

C mg 45-80

Bi mg 1.5

B ₂ mg 1.2-1.8

B ₆ mg 2.0-2.5

Nicotinamide mg 12-20

Folic acid mg 0.4-0.8

^B 12 µg 3.0-4.0

The following daily amounts are preferred for minerals: sodium 1-10 g

Potassium 2-6 g

Magnesium 200-600 mg

Calcium 0.5-1.5 g.

Suitable daily doses for trace elements are e.g. B .:

Element feed

(mα / Taα.

Fe 15

F 2.5

Zn 6-22

Si 0.1-2 g

Cu 3.2

V 2

Se 0.07

Mn 2-9

J 0.2

Sn 4.0

Ni 0.4

Mo 0.3

Cr 0.05-0.1 Co 0.3

AI 5-35

For e.g. B. 10 g of a daily oral combination of active ingredients according to I. a), b) and / or c) with vitamins, the following weight percentages for vitamins are preferably selected (based on the weight of the combination):

^B 12 0.000001 - 0.00001

Nicotinamide 0.12-0.2

B ₆ 0.020 - 0.025

B2 0.012 - 0.018

B1 0.01-0.02

Vit. C 0.4 - 20

Vit. E 0.01 - 0.2

Vit. D 0.00001 - 0.0001

Vit. A 0.015 - 0.02

If one selects daily doses other than the 10 g of the combination indicated above, for example, in the case of larger quantities, a numerically correspondingly lower percentage by weight for the vitamin portion must be selected, so that the desired daily vitamin intake is ensured. The opposite applies accordingly to the choice of smaller quantities. The person skilled in the art can readily carry out this coordination.

A combination of 10 g (daily dose) as stated above, but which contains minerals, can e.g. B. 1-20 wt .-% CaCl ₂ , preferably 5-15 wt .-%. The same applies to other minerals, trace elements and the other active substances or groups according to II.

The combinations according to II. Can also be incorporated into topical preparations.

It is understandable for the person skilled in the art that lipophilic substances, which on the one hand are more easily absorbed and on the other hand are stored in the body's own fatty tissue, must be more limited in their daily dose than hydrophilic substances which can easily be excreted in the event of an overdose.

SPARE BLADE (RULE 26) The strongly varying use concentrations of the substances mentioned below result from these ratios.

Combinations of oils as described under I. a) are preferred

1) selenium

2) Vitamin E / D-α-tocopherol acetate

3) with 1) + 2).

For oral administration of the combination of I. a) with 1) selenium, preferably 0.001-0.01% by weight of 1) selenium is administered for a daily dose of 10 g of I. a).

For oral administration of 10 g of the combination of I. a) with 2) vitamin E, 1-6% by weight of vitamin E is preferably combined with 94-99% by weight of the components described under I. a).

For oral administration of 10 g I. a) with 1) and 2), 1-6% by weight of vitamin E with 0.001-0.01% by weight of selenium and 98.999-93.99% by weight are preferred (rest ) a) combined.

For topical application, the 5-10 times the amount of the orally used doses of and I. a) and 1) and 2) components are incorporated as a daily dose in the corresponding formulations, as explained below.

Topical preparations containing vitamins and / or trace elements and / or minerals are preferred.

Vitamins D, its derivatives or vitamin A or its derivatives are preferably present in the topical preparations in amounts of 0.001-0.1% by weight, particularly preferably 0.005-0.05% by weight.

For the topical supply of other vitamins, in particular those mentioned, or the other active substances according to II., Amounts are preferably selected which are about five to ten times the specified or known, for. B. Average daily oral doses. Accordingly, taking into account the daily application quantities, the weight percentages of these substances are in the topical ones

SPARE BLADE (RULE 26) To choose preparations so that such 5-10 times the amounts are available. The person skilled in the art can carry out this quantity adjustment with ease.

According to the invention, pharmaceutical preparations, agents or compositions are also created which contain the compounds according to the invention or their pharmaceutically acceptable derivatives together with a pharmaceutically acceptable diluent or carrier.

The compounds of the present invention can be administered orally or parenterally or rectally, e.g. B. in a dosage of 10 mg to 800 g, preferably 1 g to 100 g, particularly preferably 2 g to 10 g per day, in particular also in divided doses, for example twice to four times a day.

In particular, the compounds according to the invention and the combinations according to the invention can also be easily incorporated into conventional pharmaceutical and cosmetic bases for topical applications, and the corresponding topical pharmaceutical and cosmetic preparations or agents are thus obtained. They are preferred in amounts of 0.1 to 99.5% by weight, preferably also in amounts of 1 to 50% by weight, in particular in amounts of 2 to 30% by weight, in each case based on the total weight of the topical agent. The preparations can be used several times a day in the usual way.

The invention also relates to the use of the active compounds according to the invention for producing pharmaceutical agents, topical pharmaceutical and cosmetic agents for the prophylaxis and treatment of the conditions according to the invention.

The invention also relates to the use of pharmaceutical agents and topical pharmaceutical and cosmetic agents containing active ingredients according to the invention for the prophylaxis and treatment of the above conditions.

Treatment of psoriasis and atopic dermatitis is particularly preferred.

SPARE BLADE (RULE 26) The active compounds according to the invention can be mixed with customary pharmaceutically acceptable diluents or carriers and, if appropriate, with other auxiliaries and administered, for example, orally or parenterally or rectally. You can preferably take orally in the form of powder, granules, capsules, pills, tablets, film-coated tablets, dragees, syrups, emulsions, suspensions, dispersions, aerosols and solutions as well as liquids, or as suppositories, vaginal balls or parenterally, e.g. B. in the form of liquids and solutions, emulsions or suspensions, for example as infusion solutions. Oral preparations can contain one or more additives such as sweeteners, flavoring agents, colorants and preservatives. Tablets can contain the active ingredient mixed with customary pharmaceutically acceptable auxiliaries, for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate, stearic acid and talc.

Suitable carriers are, for example, milk sugar (lactose), gelatin, corn starch, stearic acid, ethanol, propylene glycol, ether of tetrahydrofurfuryl alcohol and water.

The formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, z. B. in the case of the use of water as a diluent, organic solvents can optionally be used as auxiliary solvents.

The application is carried out in the usual way, preferably rectally, orally or parenterally, in particular orally or intravenously. In the case of oral use, tablets can of course also contain additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned. Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting. In the case of aqueous suspensions and / or elixirs which are intended for oral use, the active compounds can

SPARE BLADE (RULE 26) Except with the above-mentioned auxiliaries, various flavor enhancers or colorants can be added.

In the case of parenteral use, solutions of the active ingredients can be used using suitable liquid carrier materials.

Capsules can contain the active ingredient as a single ingredient or mixed with a solid diluent such as calcium carbonate, calcium phosphate or kaolin. The injectable preparations are also formulated in a manner known per se (ampoules, bottles).

The pharmaceutical preparations can contain the active ingredient in an amount of 0.1 to 90 percent by weight, in particular 1-90 percent by weight. Capsules are particularly preferred. Individual doses contain the active substances preferably in an amount of 100 to 600 mg.

If salts are sparingly soluble in water, they can be administered in the form of slurries. The sodium and potassium salts have a particularly good solubility in water. For example, salts are preferably injected intravenously or intramuscularly in the form of an aqueous solution such as physiological saline.

The topical compositions according to the invention can be formulated as liquid, pasty or solid preparations, for example as aqueous or alcoholic solutions, aqueous suspensions, emulsions, ointments, creams, oils, powders, powders or sticks. Depending on the desired formulation, the active ingredients can be incorporated into pharmaceutical and cosmetic foundations for topical applications which, as further components, include, for example, oil components, fat and waxes, emulsifiers, anionic, cationic, ampholytic, zwitterionic and / or nonionic surfactants, and lower polyhydric alcohols, water, preservatives, buffers, thickeners, fragrances, dyes and opacifiers. Emulsions, e.g. B. W / O emulsions using oils and fats per se or ointments.

Furthermore, it is preferred according to the invention to add antioxidants to the active ingredients and the preparations, the pharmaceutical and topical agents. The use of natural or nature-identical compounds is particularly preferred

SPARE BLADE (RULE 26) such as tocopherols. The antioxidants mentioned are in the agents according to the invention, for. B. in amounts of 0.01 - 5 wt .-%, in particular from 0.5 - 2 wt .-%, based on the total agent. They serve to stabilize the active ingredient.

The invention is primarily seen in the use of pharmaceutical or cosmetic compositions, but it is also possible to incorporate the active ingredients in dietary additives, in dietary margarine or other foods. The use of these foods, which may contain other active materials and are referred to herein as dietary or pharmaceutical compositions, are within the scope of the invention.

It is to be understood that when disorders of a kind occur which require treatment of animals, the invention, although primarily described for human medicine, is applicable to veterinary medicine.

Unless otherwise stated, amounts and percentages in the context of the present application are based on the weight and the total composition of the preparation.

Test report

The surprising effect of the active compounds according to the invention was demonstrated in a clinical examination with olive oil: Included patients: 35.

The patients received 3.6 g of olive oil / day for 12 weeks (orally, in capsules).

Indication: Psoriasis vulgaris of the chronic stationary type with a Psoriasis and Severity Score (PASI) of at least 10. The Psoriasis Area and Severity Index is a measure for the quantification of psoriasis symptoms according to Fredriksson and Pettersson (1978).

Possible interferences, such as B. other organ findings, abnormal serum values, other psoriasis therapy, climatic influences.

SPARE BLADE (RULE 26) Results:

The clinical condition was improved by at least 43%.

In patients with olive oil without additional concomitant medication (for other diseases, such as high blood pressure), an improvement of at least 50% was achieved. These decreases in the PASI score are statistically significant.

In previous clinical studies, olive oil was only used as a placebo with no therapeutic effect. The investigation thus shows that the active compounds according to the invention have a significantly strong activity against the diseases according to the invention, such as psoriasis.

It is to be understood that the absolute amount of active ingredients present in any dosage unit should not exceed the amount appropriate for the rate and type of application to be carried out, but on the other hand it is also desirable to that the desired rate of application is achieved through a lower number of doses. The rate of administration will mostly depend on the precise pharmacological action that is desired.

The following examples illustrate the invention:

Example 1

One capsule containing olive oil was administered in 0.5 g capsules six times a day for the conditions listed above.

Example: 2

A capsule containing 70% olive oil and 30% salmon oil was administered in 0.5 g capsules eight times a day for the conditions as described above.

Example 3

A 0.25 g capsule containing 150 mg oleic acid and 100 mg EPA (20: 5n-3) was administered eight times a day for the conditions as described above. Example 4

A capsule containing 50 mg linoleic acid, 20 mg 22: 4n-6, 20 mg 22: 5n-6, 10 mg 20: 5n-3, 20 mg 22: 5n-3 and 20 mg 22: 6n-3 was used four times taken a day for the conditions as described above.

Example 5

Production of a cooling ointment of W / O type parts by weight of yellow wax 7

Walrat 8

Olive oil 60

Water 25

The water, which has been heated to the same temperature, is incorporated into the mixture of wax, walrus and olive oil, which has been heated to about 60 ° C. and to which a suitable antioxidant can be added. The ointment is stirred until it cools.

This ointment was applied to the affected skin areas at least twice a day as described above.

Example 6

Production of an O / W type cream

Olive oil 30 g

Cetylanum (Lanette® N) 5 g

Propylene glycol 20 g

Aqua ad 100 g

The mixture of propylene glycol + water heated to 80 C is added in portions and with constant stirring to the mixture of hardened olive oil + cetylan heated to 80 C; then it is stirred cold and the evaporated water is replaced.

SPARE BLADE (RULE 26) This cream was applied to the affected skin areas at least twice a day as described above.

Example 7

Production of an O / W type cream:

Parts by weight

Polyoxyethylene (20) sorbitan monostearate (polysorbate 60) 5

Cetylstearyl alcohol 10

Glycerol 85% 10

White Vaseline 25 a-D-tocopherol 1

Oleic acid sodium salt 5 optionally colorants, fragrances

Water ad 100

The production takes place in a manner known per se. The fat phase and the water phase are prepared separately by mixing the constituents, possibly with little heating. Then the phases are mixed and emulsified.

The cream was applied to the affected skin areas at least twice a day as described above.

Example 8

How to make a fatty ointment with olive oil:

Parts by weight of olive oil 10

Wool wax alcohol ointment DAB 10 ad 100

The wool wax alcohol ointment and the olive oil are 75 -

80 C heated and mixed. Then they are stirred until they cool. The cream was applied to the affected skin areas at least twice a day as described above.

Example 9

Ointment% by weight

Triamcinolone acetonide 0.025

Olive oil 20.0

White Vaseline ad 100

Example 10

Ointment wt% calcium chloride

(CaCI in 25% by weight aqueous solution) 10

Glycerin 10

Cetylstearyl alcohol 24

Olive oil 28

White Vaseline 28

Example 11

A capsule with the following contents was administered orally twelve times a day for the conditions mentioned:

Olive oil 500 mg

Vitamin E 11 mg

Example 12

A capsule with the following contents was administered twelve times a day for the conditions mentioned:

Olive oil 500 mg

Selenium (as sodium selenite • 5H ₂ 0) 10 μg

SPARE BLADE (RULE 26) Example 13

Ointment% by weight

Salicylic acid 3

Olive oil (in a sufficient amount to dissolve the salicylic acid) Yellow Vaseline ad 100

Example 14

ointment

The procedure was as described in Example 13, except that instead of salicylic acid

Ethyl hydrogen fumarate used.

Example 15

Ointment% by weight

Zinc oxide 50

Olive oil 50

Example 16

Cream% by weight

Polyethylene glycol sorbitan stearate 5

Cetyl alcohol 10

Olive oil 30

Glycerin 5

Arginine hydrochloride 5

Water ad 100

Example 17

A cream as described in Example 16 was prepared in a known manner, but urea was used instead of arginine hydrochloride.

SPARE BLADE (RULE 26)

Claims

1. Use of I. a) one or more components selected from the group of vegetable oils and vegetable fats and oleic acid or its derivatives and linoleic acid or its derivatives and the mixed di- or tri-glycerides or mixed phospholipids with two or more acids from the group formed from oleic acid, linoleic acid and fatty acids of the n-3 series or n-6 series, preferably at least one of the acids being oleic acid or linoleic acid, and

(b) where appropriate, at least one animal fat or animal oil; and

and

d) trace elements, e) minerals, f) vitamins, g) amino acids, h) anti-inflammatory and / or immunosuppressive substances i) antipsoriatics, j) keratolytics and / or k) urea,

for the treatment and prophylaxis of inflammatory or immunological diseases, diabetes, alcoholism and wounds. Use according to claim 1, characterized in that as vegetable oils sunflower oil, soybean oil, peanut oil, rapeseed oil, sesame oil, safflower oil, tall oil, linseed oil, rapeseed oil, mustard oil, olive oil, tea seed oil, corn oil, wheat germ oil, coriander oil, safflower oil, safflower oil, borage oil, evening primrose oil or currant seed oil or mixtures can be used.

3. Use of pharmaceutical agents and topical pharmaceutical and cosmetic and dietetic agents containing I. a) one or more components selected from the group of vegetable oils and vegetable fats and oleic acid or its derivatives and linoleic acid or its derivatives and the mixed Di- or tri-glycerides or mixed phospholipids with two or more acids from the group formed from oleic acid, linoleic acid and fatty acids of the n-3 series or n-6 series, preferably at least one of the acids being oleic acid or linoleic acid, and

(b) where appropriate, at least one animal fat or animal oil; and

and

SPARE BLADE (RULE 26) for the treatment and prophylaxis of inflammatory or immunological diseases, diabetes, alcoholism and wounds.

4. Use of I. a) one or more components selected from the group of vegetable oils and vegetable fats and oleic acid or its derivatives and linoleic acid or its derivatives and the mixed di- or tri-glycerides or mixed phospholipids with two or more acids from the group formed from oleic acid, linoleic acid and fatty acids of the n-3 series or n-6 series, preferably at least one of the acids being oleic acid or linoleic acid, and

(b) where appropriate, at least one animal fat or animal oil; and

and

of individual active substances and combinations according to I., each optionally in combination with one component or more components each selected from one or more of the following groups of

for long-term therapy, interval therapy and prophylaxis of inflammatory or immunological diseases, diabetes, alcoholism and wounds. 5. Use of I. a) one or more components selected from the group of vegetable oils and vegetable fats and oleic acid or its derivatives and linoleic acid or its derivatives and the mixed di- or tri-glycerides or mixed phospholipids with two or more acids from the group formed from oleic acid, linoleic acid and fatty acids of the n-3 series or n-6 series, preferably at least one of the acids being oleic acid or linoleic acid, and

(b) where appropriate, at least one animal fat or animal oil; and

and

for the treatment and prophylaxis of psoriasis or atopic dermatitis.

6. Use of active ingredients and preparations according to claims 1-5, characterized in that the combinations contain vitamins, minerals, trace elements and / or keratolytics, in particular vitamin E, selenium and / or salicylic acid.